S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
3 Computer Vision Stocks for Long-Term Gains From AI
Undervalued UnitedHealth Group Won’t Be For Long
Closing prices for crude oil, gold and other commodities
DocuSign and The Case for 66% Upside 
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
3 Computer Vision Stocks for Long-Term Gains From AI
Undervalued UnitedHealth Group Won’t Be For Long
Closing prices for crude oil, gold and other commodities
DocuSign and The Case for 66% Upside 
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
3 Computer Vision Stocks for Long-Term Gains From AI
Undervalued UnitedHealth Group Won’t Be For Long
Closing prices for crude oil, gold and other commodities
DocuSign and The Case for 66% Upside 
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
3 Computer Vision Stocks for Long-Term Gains From AI
Undervalued UnitedHealth Group Won’t Be For Long
Closing prices for crude oil, gold and other commodities
DocuSign and The Case for 66% Upside 

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
$0.60
$0.05
$1.97
$25.24M-0.0618,253 shs6,100 shs
Ceapro Inc. stock logo
CRPOF
Ceapro
$0.18
$0.16
$0.11
$0.44
$13.87M1.5310,070 shs6,451 shs
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
$5.51
$4.00
$6.92
$200.47M2.16189,500 shs64,100 shs
MYOS
MYOS RENS Technology
$3.35
$0.74
$3.85
$16.70M1.081.68 million shsN/A
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
0.00%0.00%0.00%0.00%0.00%
Ceapro Inc. stock logo
CRPOF
Ceapro
-2.32%-3.17%+9.46%+36.13%-60.64%
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
0.00%0.00%0.00%0.00%0.00%
MYOS
MYOS RENS Technology
0.00%0.00%-2.14%-62.47%+386.85%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Ceapro Inc. stock logo
CRPOF
Ceapro
N/AN/AN/AN/AN/AN/AN/AN/A
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
MYOS
MYOS RENS Technology
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
N/AN/AN/AN/A
Ceapro Inc. stock logo
CRPOF
Ceapro
N/AN/AN/AN/A
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
N/AN/AN/AN/A
MYOS
MYOS RENS Technology
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
$20K0.00N/AN/A($0.03) per share0.00
Ceapro Inc. stock logo
CRPOF
Ceapro
$14.49M0.96$0.06 per share2.92$0.32 per share0.55
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
$10.72M0.00N/A23.28$3.63 per share0.00
MYOS
MYOS RENS Technology
$1.03M0.00N/AN/A$0.13 per share0.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
-$1.45MN/A0.00N/AN/A-41,453.98%N/A-574.29%N/A
Ceapro Inc. stock logo
CRPOF
Ceapro
$3.38M-$0.02N/AN/A-24.95%-8.91%-7.81%N/A
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
-$8.56MN/A0.00N/AN/A-328.56%-16.12%-14.17%N/A
MYOS
MYOS RENS Technology
-$4.26MN/AN/AN/AN/A-277.82%-166.68%-104.95%N/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
N/AN/AN/AN/AN/A
Ceapro Inc. stock logo
CRPOF
Ceapro
N/AN/AN/AN/AN/A
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
N/AN/AN/AN/AN/A
MYOS
MYOS RENS Technology
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
N/A
0.03
0.07
Ceapro Inc. stock logo
CRPOF
Ceapro
N/A
11.00
7.72
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
0.14
10.10
10.10
MYOS
MYOS RENS Technology
0.11
3.78
1.94

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
N/A
Ceapro Inc. stock logo
CRPOF
Ceapro
N/A
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
19.39%
MYOS
MYOS RENS Technology
4.97%

Insider Ownership

CompanyInsider Ownership
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
34.35%
Ceapro Inc. stock logo
CRPOF
Ceapro
N/A
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
1.10%
MYOS
MYOS RENS Technology
45.30%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Amarillo Biosciences, Inc. stock logo
AMAR
Amarillo Biosciences
242.07 millionN/ANot Optionable
Ceapro Inc. stock logo
CRPOF
Ceapro
N/A78.29 millionN/ANot Optionable
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
2234.51 million34.13 millionOptionable
MYOS
MYOS RENS Technology
1512.19 millionN/ANot Optionable

MYOS, AMAR, CRPOF, and KMPH Headlines

SourceHeadline
Ren Zhengfei says US government underestimates HuaweiRen Zhengfei says US government 'underestimates' Huawei
bbc.com - December 23 at 1:17 PM
Pioneer announces The Ren as Business Partner of the YearPioneer announces The Ren as Business Partner of the Year
richlandsource.com - November 20 at 1:50 PM
Shenqiang RenShenqiang Ren
buffalo.edu - October 4 at 3:32 PM
Anthony M. Newman to Lead REN-ISAC Cybersecurity CenterAnthony M. Newman to Lead REN-ISAC Cybersecurity Center
campustechnology.com - August 27 at 9:26 PM
Carbon-based quantum technologyCarbon-based quantum technology
sciencedaily.com - August 19 at 4:05 PM
Bio-active Peptides Market Size 2023-2031 Industrial Trends by Absolute Reports | with [93 Pages]Bio-active Peptides Market Size 2023-2031 Industrial Trends by Absolute Reports | with [93 Pages]
marketwatch.com - May 11 at 1:13 AM
Latest "Bio-active Peptides Market" Size Forecast 2023-2031: New Challenges, Drivers, and RestraintsLatest "Bio-active Peptides Market" Size Forecast 2023-2031: New Challenges, Drivers, and Restraints
marketwatch.com - May 8 at 9:06 PM
Bio-active Peptides Market Size Dynamics 2023-2029Bio-active Peptides Market Size Dynamics 2023-2029
marketwatch.com - April 13 at 3:09 PM
RenQ Finance (RENQ) raises $5 million, makes some serious buzz with its all in one DeFi platformRenQ Finance (RENQ) raises $5 million, makes some serious buzz with its all in one DeFi platform
cointelegraph.com - April 6 at 1:03 PM
Global Bio-active Peptides Market: Future Extrapolations and Emerging Updates for 2023-2027Global Bio-active Peptides Market: Future Extrapolations and Emerging Updates for 2023-2027
marketwatch.com - March 21 at 9:47 AM
Bio-active Protein Market Size 2023 Research Report by Industrial Growth Analysis and Forecast till 2027Bio-active Protein Market Size 2023 Research Report by Industrial Growth Analysis and Forecast till 2027
marketwatch.com - March 13 at 10:33 AM
Can Huawei thrive despite American sanctions?Can Huawei thrive despite American sanctions?
economist.com - October 29 at 10:12 AM
Bio-active Peptides Market Size, Share, 2022 Global Trends, Development Status, Opportunities, Competitive Landscape and Growth by Forecast 2028Bio-active Peptides Market Size, Share, 2022 Global Trends, Development Status, Opportunities, Competitive Landscape and Growth by Forecast 2028
marketwatch.com - September 28 at 9:57 AM
Bio-Active Protein Market Is Likely to Experience a Strong Growth During 2022-2028 with Top Countries DataBio-Active Protein Market Is Likely to Experience a Strong Growth During 2022-2028 with Top Countries Data
marketwatch.com - August 4 at 1:49 AM
Renaissance Festival tickets go on sale Friday, Aug. 5Renaissance Festival tickets go on sale Friday, Aug. 5
independenttribune.com - August 1 at 9:38 AM
Rensair raises $7m to establish clean air as a human rightRensair raises $7m to establish clean air as a human right
wfmz.com - May 10 at 9:43 AM
Bioactive Protein Market Latest Analysis Report 2022: Global Industry Size, Share, Production, Growth Drivers and Strategic Outlook 2026Bioactive Protein Market Latest Analysis Report 2022: Global Industry Size, Share, Production, Growth Drivers and Strategic Outlook 2026
wicz.com - January 12 at 2:06 PM
Bioactive Peptide Market to See Booming Growth 2021-2028 | Archer Daniels Midland Company, Seagarden AS, Phermpep Co. Ltd., Arlak Biotech Pvt. Ltd.Bioactive Peptide Market to See Booming Growth 2021-2028 | Archer Daniels Midland Company, Seagarden AS, Phermpep Co. Ltd., Arlak Biotech Pvt. Ltd.
chipdesignmag.com - November 1 at 10:13 PM
ICYMI: Everything you need to know about the iPhone 13ICYMI: Everything you need to know about the iPhone 13
yahoo.com - September 26 at 10:38 PM
MYOS RENS Technology Inc. Common Stock (MYOS)MYOS RENS Technology Inc. Common Stock (MYOS)
nasdaq.com - July 29 at 10:47 PM

Company Descriptions

Amarillo Biosciences logo

Amarillo Biosciences

OTCMKTS:AMAR
Amarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.
Ceapro logo

Ceapro

OTCMKTS:CRPOF
Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.
Zevra Therapeutics logo

Zevra Therapeutics

NASDAQ:KMPH
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

MYOS RENS Technology

NASDAQ:MYOS
MedAvail Holdings, Inc. is a technology-enabled pharmacy company. It provides turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. The firm helps patients to optimize drug adherence, resulting in better health outcomes. The company is headquartered in Mississauga, Canada.